Hotline for Health Services for Displaced Lebanese 1787
Hotline for the Patient Admission to Hospitals 01/832700
COVID-19 Vaccine Registration Form covax.moph.gov.lb
MoPH Hotline 1214
Are you a new member? Sign up now
 
Let us help you
Read about the latest topics.

Integration of Non-Communicable Disease Services within Primary Health Care

 
Introduction
The Primary Health Care Department at the Ministry of Public Health in collaboration with WHO, launched an initiative for the integration of Non-Communicable Diseases (NCD) program within Primary Health Care centers in Lebanon, in 2012. This initiative aimed at integrating a two-step early detection of Diabetes Mellitus and Hypertension as well as estimating the Total Cardiovascular Risk among beneficiaries aged 40 years and above. The model adopted in this initiative was based on the WHO’s 2012 package of Essential Non-Communicable Diseases interventions for Primary Health Care.
The two-step screening model consists of administering initially a screening tool by the health care workers whether in the setting of the health center or in the community. Step 1 consists of using this tool which is in the form of a questionnaire that tackles information related to the beneficiaries. The health care worker would then calculate the total cardiovascular risk for the beneficiary (using the WHO/International Society of Hypertension –WHO/ISH- risk prediction charts) and would refer him/her to the next step (Step 2) in case the total cardiovascular risk was greater than 10% or there was a previous history of diabetes or hypertension. Step 2 involves performing a set of laboratory tests and a referral to the treating physician for calculation of the final cardiovascular risk.
 
Development of the Non-Communicable Disease Program
The program has passed through many phases, in each phase many centers were trained on implementing and using the NCD programs tools and protocols. All the centers within the Primary Healthcare network were trained on NCD within the time period 2013 to 2017. Training sessions were done on regular basis including 25 centers per session. The training included the healthcare workers, nursing staff, administrative staff and physicians.
 
Continuous Support
In order to maintain the sustainability of the program, POINT OF CARE testing machines for NCD screening were distributed to all involved Primary Health Care centers.
Furthermore, to sustain the accuracy of the data entered daily by the centers, an NCD e module was developed by the IT MoPH department on the Health Information System to aid the centers to enter all the NCD related data and perform the calculations necessary for diagnosis of cardiovascular risks.
The MoPH encourages the Primary Health Care centers in Lebanon to organize outreach activities, events and campaigns to raise the awareness on health factors associated with cardiovascular diseases (CVDs), such as obesity, lack of physical activity and smoking (tobacco-use). MoPH provides educational material to support these activities.
 
    ...
    77
    ...
ATC Name B/G Ingredients Dosage Form Price
C10AA03 APO-PRAVASTATIN G Pravastatin Sodium - 20mg 20mg Tablet 775,397 L.L
J01EE01 CO-TRIMOXAZOLE G Trimethoprim - 160mg, Sulfamethoxazole - 800mg Tablet 7,529,090 L.L
C09AA05 ACURIL G Ramipril - 5mg 5mg Tablet 614,136 L.L
J01EE01 CO-TRIMOXAZOLE G Trimethoprim - 160mg, Sulfamethoxazole - 800mg Tablet 183,019 L.L
A04AD GRAVOL B Dimenhydrinate - 50mg 50mg Tablet 163,949 L.L
A10BD15 XIGDUO XR B Metformin HCl XR - 1000mg, Dapagliflozin - 10mg Tablet 3,006,579 L.L
C09AA05 NORMOPRIL G Ramipril - 5mg 5mg Tablet 474,376 L.L
C09AA05 RAMIPRIL-REMEDICA G Ramipril - 5mg 5mg Tablet 623,543 L.L
C10AA05 APO-ATORVASTATIN G Atorvastatin (calcium) - 10mg 10mg Tablet 889,624 L.L
N07AX01 JAMP PILOCARPINE G Pilocarpine HCl - 5mg 5mg Tablet 3,668,690 L.L
C09AA05 TRITACE B Ramipril - 10mg 10mg Tablet 689,391 L.L
J05AG01 NEPINE G Nevirapine - 200mg 200mg Tablet 5,921,678 L.L
C09AA05 ACURIL G Ramipril - 10mg 10mg Tablet 810,337 L.L
G03GB02 CLOMID B Clomifene citrate - 50mg 50mg Tablet 274,144 L.L
N05AX08 PMS-RISPERIDONE G Risperidone - 2mg 2mg Tablet 931,283 L.L
N07BC01 BUPENSAN G Buprenorphine - 8mg 8mg Tablet 1,259,180 L.L
L04AA29 XELJANZ B Tofacitinib - 5mg 5mg Tablet L.L
G03GB02 CLOMIFERT G Clomifene citrate - 50mg 50mg Tablet 395,090 L.L
M04AC01 COLCHICINE SEID G Colchicine - 1mg 1mg Tablet 382,995 L.L
N07BC01 BUPRENORPHINE ARROW G Buprenorphine - 8mg 8mg Tablet 1,115,389 L.L
C09AA05 NORMOPRIL G Ramipril - 10mg 10mg Tablet 599,354 L.L
G03GB02 CLOMIFERT G Clomifene citrate - 50mg 50mg Tablet 395,090 L.L
M05BA04 FOSAMAX 70MG ONCE WEEKLY B Alendronate - 70mg 70mg Tablet 1,988,887 L.L
N07BC01 BUPRENORPHINE ARROW G Buprenorphine - 2mg 2mg Tablet 563,070 L.L
C09AA05 RAMIPRIL-REMEDICA G Ramipril - 10mg 10mg Tablet 896,343 L.L
G03HB01 DIANE '35' B Ethinylestradiol - 0.035mg, Cyproterone acetate - 2mg Tablet 494,534 L.L
J01FA09 KLERIMED G Clarithromycin - 500mg 500mg Tablet 686,704 L.L
M05BA04 APO-ALENDRONATE G Alendronate (monosodium trihydrate) - 70mg 70mg Tablet 981,005 L.L
G03XC01 EVA TABLET G Raloxifene HCl - 60mg 60mg Tablet 1,354,081 L.L
L04AA31 TERAGIO G Teriflunomide - 14mg 14mg Tablet L.L
    ...
    77
    ...
Sitemap
© Copyrights reserved to Ministry of Public Health 2025